Home

Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)

2.4350
+0.0550 (2.31%)

Protalix Biotherapeutics is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of rare and chronic diseases

Utilizing its proprietary oral protein manufacturing platform, the company works to produce biopharmaceuticals that can provide effective treatment alternatives for patients. Protalix is particularly dedicated to addressing unmet medical needs and improving the quality of life for individuals suffering from conditions such as enzyme deficiencies, leveraging its expertise in biochemistry and molecular biology to advance its therapeutic pipeline.

SummaryNewsPress ReleasesChartHistoricalFAQ
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSEPLX) (“Protalix”) on behalf of the company’s shareholders.
By Kaskela Law LLC · Via Business Wire · September 17, 2024
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 16, 2024
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease.
Via TheNewswire.com · November 30, 2022
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a company by looking at how options traders are trading it.
Via TheNewswire.com · September 21, 2022